Phase 2 biotech Longeveron files for a $30 million IPO - (NASDAQ via NewsPoints Desk)

  • Longeveron has filed with the US Securities and Exchange Commission to raise up to $30 million in an initial public offering, as reported in NASDAQ.

  • The company is currently sponsoring Phase I and II trials in aging frailty, Alzheimer’s disease, the metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.

  • Longeveron’s lead product, LOMECEL-B, is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. 

To read more NewsPoints articles, click here.